Which drug is NOT indicated for the treatment of multiple sclerosis?

Riluzole is not indicated for the treatment of multiple sclerosis. Instead, it is primarily used to treat amyotrophic lateral sclerosis (ALS). This difference in therapeutic use is crucial to understand, as multiple sclerosis (MS) and ALS are distinct neurological disorders with different underlying mechanisms and treatment approaches.

In contrast, the other listed drugs—teriflunomide, dalfampridine, and dimethyl fumarate—are specifically approved for the management of multiple sclerosis. Teriflunomide works as an immunomodulator, helping to reduce the frequency of relapses in MS. Dalfampridine is used to improve walking in patients with MS, while dimethyl fumarate offers anti-inflammatory and cytoprotective effects in MS treatment.

Recognizing the specific indications for each drug is vital for effective patient management and treatment planning in various neurological conditions.